- Home
- Peptides
- Immune & Inflammatory
- Thymosin Alpha-1
What Is Thymosin Alpha-1? Benefits, Research & Safety
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
Quick Facts
In This Guide
Overview
Discovery & History
Mechanism of Action
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Enhanced T cell function and maturation
- 2Improved responses to viral infections (hepatitis B and C)
- 3Vaccine response enhancement
- 4Potential adjuvant effects in cancer therapy
- 5Immune support in immunocompromised states
- 6Possible benefits in sepsis and critical illness
- 7Balanced immunomodulation rather than excessive stimulation
Theoretical Dosing & Protocols
| Theoretical Dosage | 1.6 mg subcutaneously (standard pharmaceutical dose) |
| Frequency | Twice weekly for most approved indications |
| Duration | Variable depending on indication; often 6-12 months for hepatitis |
| Notes | Thymosin Alpha-1 is an approved medication in several countries. Dosing follows established pharmaceutical protocols. Use should be under medical supervision with appropriate monitoring. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (approved route)
| Half-Life | Stability |
|---|---|
| Approximately 2 hours | Pharmaceutical formulations (Zadaxin) have defined stability; lyophilised forms should be stored appropriately |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (mild)
- Fatigue
- Mild flu-like symptoms
- Generally very well tolerated
Rare Risks & Concerns
- Allergic reactions (rare)
- Theoretical concerns in autoimmune conditions
- Limited data in pregnancy
Contraindications
- Known hypersensitivity to Thymosin Alpha-1
- Organ transplant recipients (immune stimulation may risk rejection)
- Certain autoimmune conditions (use with caution)
- Pregnancy (limited data)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Available through specialist channels in some cases.
🇪🇺 European Union
Approved in some member states; orphan drug designation for certain conditions.
Clinical Studies Summary
Thymosin Alpha-1 for Chronic Hepatitis B
Clinical trials demonstrating efficacy of Tα1 in treating chronic hepatitis B virus infection.
Thymosin Alpha-1 as Vaccine Adjuvant
Research showing enhanced vaccine responses with Tα1 co-administration.
Thymosin Alpha-1 in Sepsis and Critical Illness
Studies evaluating immune support effects in critically ill patients.
Looking for Thymosin Alpha-1?
Source research-grade Thymosin Alpha-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
TB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Learn moreThymosin Beta-4
A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.
Learn moreLL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and important immunomodulatory functions.
Learn more